Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Zoetis Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.8, while Zoetis Inc trades at $76.99 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| FNGU | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $156.76 |
52-Week Low | $13.73 | $71.91 |
Market Cap | — | $31.25B |
Enterprise Value | — | $38.54B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $28.77, down 0.45% on the day. The technical picture is mixed, with moving averages signaling bullish momentum but oscillators and a high RSI indicating overbought conditions. Recent news highlights the extreme volatility and decay inherent to its leveraged structure, with one report noting a $10,000 position losing 16% in a single session in June 2026.
The outlook is dominated by the product's high-risk, tactical nature. The opportunity lies in capturing amplified gains during strong bullish trends in mega-cap tech. The primary risk is significant capital erosion during volatile or sideways markets due to daily resetting leverage and compounding costs, making it unsuitable for long-term holding.
ZTS trades at $74.08, down 1.74% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results including $9.47B revenue, $2.67B net income, and a 28.03% net margin, but missed Q1 2026 EPS estimates. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU.
Despite near-term legal overhangs and a recent earnings miss, ZTS maintains robust profitability and a consensus price target of $101.43 implies significant upside. Key risks include litigation outcomes and competitive pressures in the companion animal segment, while solid cash flow and high ROE support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
